Vitrolife

Vitrolife EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Vitrolife (VITR.ST) as of Nov 10, 2026 is 29.55. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 16.87 — a change of 75.14% (higher).

EV/FCF

29.55

YoY

75.14%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Vitrolife is 2025 29.55 . EV/FCF (Enterprise Value to Free Cash Flow) of Vitrolife was 2024 16.87 . It decreases by 75.14% higher compared to the previous year.

The Vitrolife EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
72.69 SEK
Jan 1, 2019
37.35 SEK
Jan 1, 2020
35.34 SEK
Jan 1, 2021
45.52 SEK
Jan 1, 2022
26.31 SEK
Jan 1, 2023
21.99 SEK
Jan 1, 2024
16.87 SEK
Jan 1, 2025
29.55 SEK
The Vitrolife EV/FCF history
YEAREV/FCFYoY
29.55+75.14%
16.87-23.25%
21.99-16.45%
26.31-42.20%
45.52+28.80%
35.34-5.38%
37.35-48.61%
72.69+76.81%
41.11-45.55%
75.50+2.44%
73.71-20.58%
92.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vitrolife Stock analysis

What does Vitrolife do? Vitrolife AB is a Swedish biotech company specializing in the development and marketing of products for in vitro fertilization (IVF) and regenerative medicine. It was founded in 1994 and has over 390 employees worldwide. The company's main business is IVF, offering a wide range of essential products for IVF treatment such as culture media, devices for semen analysis and preparation, embryo transfer techniques, and products for biopsy examinations and cryopreservation. Vitrolife has a presence in 110 countries and has expanded its market to China where there is a high demand for fertility treatments. The company also offers medical equipment for regenerative treatments. Vitrolife is a leading player in the IVF industry known for its high product quality and innovation. It collaborates with universities and research institutions globally to improve IVF technology and success rates. The company places importance on sustainability and environmental protection, using 100% animal-free ingredients in their culture media and practicing recycling and waste reduction in their production facilities. In summary, Vitrolife offers a wide range of products for IVF and regenerative medicine, with a focus on supporting IVF treatments. The company is a leader in its industry and actively participates in research. It is committed to sustainability and environmental responsibility. Vitrolife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vitrolife stock

EV/FCF (Enterprise Value to Free Cash Flow) of Vitrolife is 29.55 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Vitrolife changed from 16.87 to 29.55, representing a 75.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Vitrolife since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Vitrolife with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Vitrolife

All Key Metrics — Vitrolife